Clinical trials: PSMA PET
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
This trial studies the effect of androgen receptor signaling inhibitors on 68Ga-PSMA-11 PET/CT imaging in patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT04279561
- Testing
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer (Adenocarcinoma)
Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer
The introduction of PSMA diagnostics and therapy has fundamentally changed the treatment management of prostate cancer and has significantly replaced other clinical and radiological diagnostic methods.
- Trial name
- NCT06820333
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Prostate Cancer
PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer
The overall objective of this Early Phase Clinical Trial is to begin defining the accuracy of 68Ga-PSMA-11 for detecting the location and size of clinically significant prostate cancer lesions in low and intermediate risk…
- Trial name
- NCT03429244
- Testing
- 68Ga-PSMA-11 PET-MRI
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Indiana University
Prostate Cancer
A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.
The purpose of this research is to test whether a new investigational Molecular Imaging (MI) agent called 61Cu-NU101 is equal to or better than a currently used MI agent, Pylarify, for the detection of prostate cancer metastases.
- Trial name
- NCT07635524
- Testing
- Cu-NU101
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Prostatic Neoplasms, Prostate Cancer
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
This investigator-initiated, prospective study evaluates the diagnostic utility of rhPSMA-7.3 (¹⁸F) PET/CT (flotufolastat F18, marketed as POSLUMA®) in men with biopsy-proven, low-risk or favorable intermediate-risk prostate…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- NCT07285057
- Testing
- rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Oligometastatic Hormone-Sensitive Prostate Cancer, Prostate Adenocarcinoma
Prospective Study on the Role of Radical Prostatectomy in Oligo-metastatic Hormone-sensitive Prostate Cancer in Patients on Androgen Deprivation Therapy
MAZINGA is a prospective, single-group pilot study evaluating disease control after robot-assisted radical prostatectomy with extended pelvic lymph-node dissection in men with oligometastatic hormone-sensitive prostate…
- Trial name
- MAZINGA (NCT07766486)
- Testing
- Robot-Assisted Radical Prostatectomy With Extended Pelvic Lymph-Node Dissection
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Neurodegenerative Diseases, Brain Neoplasms
Clinical Application of the Prototype J-PET Device
Positron emission tomography (PET) is a diagnostic imaging technique that uses positron emission (e-) to image changes in diagnosed tissues. Detector systems are an important part of PET scanners.
- Conditions
- Neurodegenerative Diseases, Brain Neoplasms, Neuroendocrine Tumors
- Trial name
- JPETClinic (NCT06211803)
- Testing
- Positron-Emission Tomography Imaging
- Where
- Poland
- Volunteers
- 10 people
- Sponsor
- Jagiellonian University
Prostate Cancer, Recurrent Prostate Cancer
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
This study will enroll 60 patients previously enrolled to MCC#18523, "A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non-African American Men with Prostate Cancer…
- Trial name
- NCT03495427
- Testing
- F-DCFPyL Injection, PSMA PET
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Newly Diagnosed, Treatment-naïve Prostate Cancer
A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer
Brief Summary： Under the support of the PROMISE scoring criteria, PSMA PET has demonstrated significant prognostic value. However, previous studies on PSMA PET included patients with various stages of prostate cancer, and the…
- Trial name
- PSMA-VISION (NCT07474142)
- Testing
- Not provided
- Where
- 9 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Xijing Hospital
Prostatic Neoplasms
The Application Value of 18F-prostate-specific Membrane Antigen PET/CT in Prostate Cancer
Prostate cancer (PCa) is the most common type of malignant tumor and the third leading cause of cancer-associated mortality among men worldwide.
- Trial name
- NCT04521894
- Testing
- Positron emission tomography/computerized tomography (PET/CT)
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Prostate Cancer
Prostate MRI and Pylarify PSMA PET/CT
This is a voluntary research study to find out how using technology including advanced magnetic resonance imaging (MRI) and prostate-specific membrane antigen - positron emission tomography (PSMA-PET) scan imaging, in addition to…
- Trial name
- NCT05568537
- Testing
- Pylarify Piflufolastat Flourine-18 (18F-DCFPyL)
- Sponsor
- Corewell Health East
Prostate Cancer, Biochemical Relapse Fo Malignant Neoplasm of Prostate
PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE
This observational study was designed to evaluate progression free survival after PSMA-PET/CT based salvage approach for patients affected by biochemical relapse after radical prostatectomy.
- Conditions
- Prostate Cancer, Biochemical Relapse Fo Malignant Neoplasm of Prostate, Prostate Adenocarcinoma, Prostate Cancer Recurrent
- Trial name
- PSICHE (NCT05022914)
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Renal Cell Carcinoma
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
The purpose of this study is to test a novel diagnostic PET imaging agent for safety and biodistribution. The agent binds PSMA and is designed to detect Prostate Specific Membrane Antigen expressing tumors, such as has been…
- Trial name
- NCT03427476
- Testing
- CTT1057
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cancer Targeted Technology
Prostate Cancer, Prostate Adenocarcinoma
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate
- Trial name
- Solar-Recur (NCT06235099)
- Testing
- Copper Cu 64 PSMA I&T
- Where
- 31 sites in United States
- Volunteers
- 235 people
- Sponsor
- Curium US LLC
Prostate Cancer
Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients
Several studies have shown a great potential of 68Ga-PSMA PET in high risk prostate cancers patients and a high detection rate than 18F-Choline PET.
- Trial name
- TePSMAG-68 (NCT03344822)
- Testing
- 68Ga-PSMA-11, 18F-Choline PET-CT
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Central Hospital, Nancy, France
Prostatic Neoplasms
Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient
It is a cross sectional study aimed to correlate between PSA Levels and F-18 PSMA PET/CT Scan findings and to evaluate the impact of PET/CT findings on the patient management
- Trial name
- NCT06209853
- Testing
- PSMA PET/CT
- Where
- Egypt
- Volunteers
- 59 people
- Sponsor
- Assiut University
Bladder Cancer
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
The purpose of this study is to see whether 68Gallium PSMA-PET/CT scans are an effective way to detect sites of cancer in people with metastatic bladder cancer or skin cancer.
- Trial name
- NCT05562791
- Testing
- [68Ga]PSMA, PET/CT imaging
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)
Significant advances in molecular nuclear medicine imaging in prostate cancer have been achieved in recent years. In particular, the introduction of prostate-specific membrane antigen (PSMA) -based tracers has significantly…
- Trial name
- ProsTone (NCT04271579)
- Testing
- Salvage Lymphnode dissection
- Where
- Germany
- Volunteers
- 397 people
- Sponsor
- Martini-Klinik am UKE GmbH
Prostate Cancer, Prostate Adenocarcinoma
Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer
Single-arm, open-label, phase II trial in 200 competent adult male patients with Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-3 and progressive metastatic prostate cancer, failing, failed, refused, not…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostatic Neoplasms, Metastatic Prostate Cancer
- Trial name
- CROSSBOW (NCT04085991)
- Testing
- 131I-PSMA-1095 Radioligand Therapy (RLT)
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
This clinical trial was done to show whether a radioactive drug (I-131-1095) that binds to prostate-specific membrane antigen (PSMA) is useful in treating metastatic prostate cancer that is positive for PSMA.
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate
- Trial name
- ARROW (NCT03939689)
- Testing
- I-131-1095, Enzalutamide
- Where
- 27 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Progenics Pharmaceuticals, Inc.